ARVN - NASDAQ

Arvinas, Inc.

ARVN·NASDAQ

$7.70

-3.8%

HealthcareBiotechnology

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$496.81M

EPS-1.2800

P/E Ratio-6.02

Earnings Date07/30/2026

arvn

Operating Expenses

Last Annual Value

372.30M

3-Year CAGR

-2%

5-Year CAGR

20%

10-Year CAGR

32%

Adjust for Inflation

Arvinas, Inc. Competitors Analysis of Operating Expenses

ARVN · NASDAQ

Company	Operating Expenses	CAGR 3Y	CAGR 5Y	CAGR 10Y
Arvinas, Inc. NASDAQ:ARVN	372.30M	-8.1%	9.0%	32.0%
Day One Biopharmaceuticals, Inc. NASDAQ:DAWN	268.72M	9.3%	29.9%	N/A
Geron Corporation NASDAQ:GERN	232.97M	6.3%	15.1%	20.3%
Iovance Biotherapeutics, Inc. NASDAQ:IOVA	659.57M	13.5%	14.0%	28.5%
Replimune Group, Inc. NASDAQ:REPL	261.63M	13.9%	27.2%	N/A
Erasca, Inc. NASDAQ:ERAS	128.30M	-2.4%	0.7%	N/A
Astria Therapeutics, Inc. NASDAQ:ATXS	111.56M	10.3%	-10.6%	12.1%
Ginkgo Bioworks Holdings, Inc. NYSE:DNA	453.91M	-24.7%	-25.8%	N/A
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP	177.53M	33.5%	82.8%	N/A
MeiraGTx Holdings plc NASDAQ:MGTX	182.52M	6.5%	10.6%	24.7%

Arvinas, Inc. Fair Value Envelope

ARVN · NASDAQ

Our analysis suggests that ARVN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.7, this represents a potential HIDDEN relative to our calculated worth for Arvinas, Inc..

HIDDEN

Intrinsic Value

Current Price: $7.7

Related Guides

Blog Categories

Continue your ARVN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.